Apollo Hospitals Enterprise Limited vs AstraZeneca Pharma India Limited

A side-by-side comparison of Apollo Hospitals Enterprise Limited (APOLLOHOSP) and AstraZeneca Pharma India Limited (ASTRAZEN) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, Apollo Hospitals Enterprise Limited leads APOLLOHOSP vs ASTRAZEN on 8 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation31
  • Profitability13
  • Growth11
  • Size & financial health31
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

APOLLOHOSP takes 3/4

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

58.43
P/E ratio
79.08
13.46
P/B ratio
19.65
0.22%
Dividend yield
0.52%
₹135.04
EPS
₹75.01

Profitability

ASTRAZEN takes 3/4

How efficiently each company turns capital and sales into profit. Higher is better.

20.48%
Return on equity
21.49%
17.31%
Return on capital
26.10%
14.94%
EBITDA margin
11.51%
7.94%
Net margin
8.24%

Growth

Even

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

14.94%
Revenue CAGR (3Y)
31.40%
33.35%
Profit CAGR (3Y)
23.73%

Size & financial health

APOLLOHOSP takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1.13L Cr
Market cap
₹14,915 Cr
₹25,229 Cr
Revenue
₹2,276 Cr
₹2,003 Cr
Net profit
₹188 Cr
0.90
Debt / equity
0.13
Apollo Hospitals Enterprise Limited
  • + ["Company has delivered good profit growth of 71.0% CAGR over last 5 years", "Company has delivered good sales growth of 19.0% CAGR over last 5 years"]
  • − ["Stock is trading at 11.97 times its book value"]
AstraZeneca Pharma India Limited
  • + ["Company has delivered good profit growth of 15.1% CAGR over last 5 years", "Company has a good return on equity (ROE) track record: 3 Years ROE 21.1%", "Company has been maintaining a healthy dividend payout of 48.0%", "Company has delivered good sales growth of 22.8% CAGR over last 5 years"]
  • − ["Stock is trading at 17.10 times its book value"]
Apollo Hospitals Enterprise Limited full analysis AstraZeneca Pharma India Limited full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.